FY2018 EPS Estimates for Oramed Pharmaceuticals, Inc. (ORMP) Lifted by Zacks Investment Research

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) – Analysts at Zacks Investment Research boosted their FY2018 earnings per share (EPS) estimates for Oramed Pharmaceuticals in a report issued on Monday. Zacks Investment Research analyst G. Zeng now anticipates that the biotechnology company will post earnings of ($1.20) per share for the year, up from their previous forecast of ($1.53). Zacks Investment Research also issued estimates for Oramed Pharmaceuticals’ FY2019 earnings at ($1.65) EPS, FY2020 earnings at $0.49 EPS and FY2021 earnings at $1.87 EPS.

A number of other analysts also recently issued reports on the company. B. Riley restated a “buy” rating and issued a $20.00 price target on shares of Oramed Pharmaceuticals in a research report on Tuesday, January 16th. ValuEngine upgraded Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Finally, HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Oramed Pharmaceuticals in a research report on Wednesday, November 22nd.

Shares of Oramed Pharmaceuticals (NASDAQ ORMP) traded down $0.07 on Thursday, reaching $8.07. The company had a trading volume of 14,150 shares, compared to its average volume of 41,259. Oramed Pharmaceuticals has a 12 month low of $5.85 and a 12 month high of $11.34.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its quarterly earnings results on Wednesday, November 29th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter. Oramed Pharmaceuticals had a negative return on equity of 49.94% and a negative net margin of 169.17%.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Susquehanna International Group LLP bought a new stake in Oramed Pharmaceuticals in the third quarter worth $185,000. Virtu KCG Holdings LLC bought a new stake in shares of Oramed Pharmaceuticals during the second quarter worth $125,000. Finally, Wells Fargo & Company MN lifted its position in shares of Oramed Pharmaceuticals by 4.4% during the second quarter. Wells Fargo & Company MN now owns 14,725 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 625 shares during the last quarter. Institutional investors own 1.92% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “FY2018 EPS Estimates for Oramed Pharmaceuticals, Inc. (ORMP) Lifted by Zacks Investment Research” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/02/01/fy2018-eps-estimates-for-oramed-pharmaceuticals-inc-ormp-lifted-by-zacks-investment-research.html.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Earnings History and Estimates for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply